Despite macroeconomic issues, the biotech industry thrives on innovation, demand, and technical breakthroughs. Its durability, flexibility, and ability to attract investment and foster collaborations all help to ensure its success.
Given the industry’s growth prospects, investors could consider buying fundamentally sound biotech stocks Protalix BioTherapeutics, Inc. (PLX), Alnylam Pharmaceuticals, Inc. (ALNY), and Jazz Pharmaceuticals plc (JAZZ) for solid returns in 2024.
